Sign up for the QMED & MD+DI Daily newsletter.
Drug-Eluting Stent Fears: Legitimate Concern or Overreaction?
After the Wall Street Journal reported that some leading U.S. hospitals have cut back on use of drug-eluting stents because of concerns they could cause blood clots, shares of the makers of the two U.S. drug-eluting stents, Johnson & Johnson and Boston Scientfic, dropped on the news. This despite the Journal saying that the hospitals are not "drastically curbing" their use.
June 26, 2006
1 Min Read
Wall Street traders aren't the only ones who may have misinterpreted the news: Last week a friend who saw the report mentioned to me about the products being "dangerous," when the article said no such thing. The concern is that the polymers used to elute the drugs might be causing clots. But there is no definitive proof yet, nor is there evidence that those risks, if they exist, outweigh the benefits of the enhanced performance drug-eluting stents bring compared to bare-metal stents. So bring on more research, and let this be a reminder how even accurately reported bad news can become overblown quickly.
You May Also Like
Empatica Launch Next-Gen FDA-Cleared Epilepsy WatchMar 1, 2024|2 Min Read
Safeguard Medical Devices: A Complete Approach to Device Lifecycle SecurityApr 4, 2024|13:00 EDT
Boston Sci Nabs FDA Approval for Agent DCBMar 1, 2024|2 Min Read
Masimo Takes Apple's Hail Mary Pass in StrideFeb 29, 2024|3 Min Read